Parasomnias D020447

Diseases [C] » Nervous System Diseases [C10] » Sleep Wake Disorders » Parasomnias

Psychiatry and Psychology [F] » Mental Disorders [F03] » Sleep Wake Disorders » Parasomnias

Description

Movements or behaviors associated with sleep, sleep stages, or partial arousals from sleep that may impair sleep maintenance. Parasomnias are generally divided into four groups: arousal disorders, sleep-wake transition disorders, parasomnias of REM sleep, and nonspecific parasomnias. (From Thorpy, Sleep Disorders Medicine, 1994, p191)   MeSH

Hierarchy View

View MeSH Tree

Subtype Terms (7)

Nocturnal Myoclonus Syndrome
 

Nocturnal Paroxysmal Dystonia
 

REM Sleep Parasomnias
 

Restless Legs Syndrome
42 drugs (32 approved, 10 experimental)

Sleep Arousal Disorders
 

Sleep Bruxism
9 drugs (7 approved, 2 experimental)

Sleep-Wake Transition Disorders
5 drugs (4 approved, 1 experimental)


Organization Involved with Phase 4 Indications (54)

AstraZeneca

Boehringer Ingelheim

Chang Gung University

Child and adolescent Psychiatric department, South Jutland

Chungnam National University

CJ HealthCare Corp.

Cleveland Sleep Research Center

Clinique Beau Soleil

Competence Centre for Transcultural Psychiatry

Crohn's and Colitis Foundation

Danish Center for Sleep Medicine

Department of Veteran Affairs

Forest Laboratories

Foundation for a Smoke-Free World

Gilead Sciences

Harvard University

Inje University

Integrated Therapeutics Group

Janssen Pharmaceutica NV

Johns Hopkins University

Kuhnil Pharmaceutical Co., Ltd.

LinkDoc Technology (Beijing) Co. Ltd.

Mayo Clinic

Mental Health Services in the Capital Region, Denmark

Merck

Midtown Medical Center, Tampa, FL

National Institute on Drug Abuse (NIDA)

Pfizer

Region of Southern Denmark

Region Syddanmark

Rose Research Center, LLC

Shaanxi Buchang Pharmaceutical Co., Ltd

Shanghai University of Traditional Chinese Medicine

Soochow University

Soonchunhyang University

SouthWest Cleveland Sleep Center

SRI International

Sungkyunkwan University

Sunovion

Takeda

Technical University of Dresden

Teva

TTY Biopharm

University of Arizona

University of California, San Diego

University of Liege

University of North Carolina at Chapel Hill

University of Paris

University of Pittsburgh

University of Southern Denmark

University of Ulsan

Vanda Pharmaceuticals

Wyeth

Yonsei University

Organization Involved with Phase 3 Indications (34)

Australia and New Zealand Breast Cancer Trials Group

Avadel Pharmaceuticals

Bioprojet

Cancer and Leukemia Group B (CALGB)

Cephalon

Dutch Kidney Foundation

Free University of Amsterdam

GlaxoSmithKline

Herlev Hospital

Hoosier Cancer Research Network

International Breast Cancer Study Group

Koege and Roskilde Hospital

Kurume University

Loma Linda University

Lundbeck

Meander Medical Center

National Cancer Institute (NCI)

National Taiwan University

Neurim Pharmaceuticals Ltd.

Neurocenter of Southern Switzerland, Lugano

Nobel Pharmaceuticals

Pennsylvania State University

Peter MacCallum Cancer Centre

Pharma Nord

Psychiatric Research Unit, Region Zealand

Southeast Renal Research Institute

Steno Diabetes Center Copenhagen

Targeted Medical Pharma

Universidade Federal do Parana

University of Brasilia

University of Cincinnati

University of Copenhagen

University of London

XenoPort, Inc.

Organization Involved with Phase 2 Indications (31)

American Academy of Sleep Medicine

Autism Treatment Network

British Columbia Cancer Agency

Case Western Reserve University

China Medical University

Clinilabs

Damon Runyon Cancer Research Foundation

Department of Defense

Health Resources and Services Administration (HRSA)

Kyowa Hakko Kirin

Kyowa Kirin

Melbourne Health

National Center for Complementary and Integrative Health (NCCIH)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institutes of Health (NIH)

Northern California Institute of Research and Education

Office of Dietary Supplements (ODS)

Rhode Island Hospital

Sanofi

Sanofi-Synthelabo

Sleep Disorders Center of Atlanta

The EMMES Corporation

The Florey Institute of Neuroscience and Mental Health

University of Colorado

University of Colorado, Denver

University of Michigan

University of New South Wales

University of Texas at Houston

University of Zurich

Wake Forest University

Organization Involved with Phase 1 Indications (9)

Abbott

Anesco North Broward LLC

Canadian Cancer Trials Group

LIfe Extension

McGill University

National Human Genome Research Institute (NHGRI)

Queen's University, Belfast

Sponsor GmbH

University of California, San Francisco

Organization Involved with Other Experimental Indications (13)

Baylor University

Huntington's Disease Society of America

Institute of Liver and Biliary Sciences, India

Jazz Pharmaceuticals

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

Oregon Health and Science University

Stanford University

Thomas Jefferson University

United States Army

University of Colorado, Boulder

University of Nebraska

University of Washington

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.